Intellia Therapeutics (NASDAQ:NTLA) released its earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.04, Bloomberg Earnings reports. The company had revenue of $10.43 million during the quarter, compared to the consensus estimate of $9.43 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. Intellia Therapeutics’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.51) EPS.
Shares of Intellia Therapeutics stock opened at $15.66 on Friday. The company has a market capitalization of $699.47 million, a price-to-earnings ratio of -7.91 and a beta of 2.80. Intellia Therapeutics has a one year low of $11.03 and a one year high of $32.95.
In related news, EVP Andrew Schiermeier purchased 7,500 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average cost of $15.72 per share, with a total value of $117,900.00. Following the purchase, the executive vice president now directly owns 3,250 shares of the company’s stock, valued at $51,090. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.10% of the stock is owned by insiders.
A number of analysts recently weighed in on NTLA shares. Chardan Capital restated a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Wednesday, February 27th. BTIG Research started coverage on Intellia Therapeutics in a research report on Thursday, February 7th. They issued a “buy” rating and a $20.00 target price for the company. BidaskClub upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Finally, Evercore ISI started coverage on Intellia Therapeutics in a research report on Thursday, April 11th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $29.08.
COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics (NTLA) Announces Earnings Results, Beats Expectations By $0.04 EPS” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2019/05/02/intellia-therapeutics-ntla-posts-earnings-results-beats-estimates-by-0-08-eps.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Further Reading: What are momentum indicators and what do they show?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.